One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study
ShalenderBhasinMBBSa†A. MichaelLincoffMDb†ShehzadBasariaMDaDouglas C.BauerMDcWilliam E.BodenMDdGlenn R.CunninghamMDeDeborahDaveyRNbElenaDubcencoMD, MSfSandraFukumotoMBAfMichelleGarciaRN, BSNbChristopher B.GrangerMDgVidyasagarKalahastiMD, FACCbMohitKheraMD, MBA, MPHeMichael G.MillerPharmDfLisa M.MitchellRN, BSNbMichael P.O'LearyMD, MPHhKarol M.PencinaPhDaPeter J.SnyderMDi…Steven E.NissenMDb
doi : 10.1016/j.ahj.2021.11.016
Volume 245, March 2022, Pages 41-50
Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation – The NOVA Study
Jonathan P.PicciniMD, MHSaAndersAhlssonMD PhDbPaulDorianMD CM MSccMarc A.GillinovMDdPeter R.KoweyMDeMichael J.MackMDfCarmelo A.MilanoMDgLouis P.PerraultMD PhDhJonathan S.SteinbergMDiNathan H.WaldronMD MHSaLawrence M.AdamsPharmDjDavid B.BharuchaMD PhDkMitchell F.BrinMDlWilliam G.FergusonPhDmStefanoBenussiMD PhDn
doi : 10.1016/j.ahj.2021.10.114
Volume 245, March 2022, Pages 51-59
The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial☆
Michael G.NannaMD, MHSaSreekanthVemulapalliMDbChristopher B.FordyceMD, MHS, MSccDaniel B.MarkMDbManesh R.PatelMDbHussein R.Al-KhalidiPhDbMichelleKelseyMDbBethMartinezBSbEricYowMSbSarahMullenMBTdGregg W.StoneMDeOriBen-YehudaMDfJames E.UdelsonMDgCampbellRogersMDdPamela S.DouglasMDb
doi : 10.1016/j.ahj.2021.12.004
Volume 245, March 2022, Pages 136-148
Cardiovascular determinants of impaired placental function in women with cardiac dysfunction
Anne S.SiegmundMD, PhDaPetronella G.PieperMD, PhDaCaterina M.BilardoMD, PhDbSanne J.GordijnMD, PhDbT. YeeKhongMDcWilfriedGyselaersMD, PhDdDirk J.van VeldhuisenMD, PhDaMichael G.DickinsonMD, PhDa
doi : 10.1016/j.ahj.2021.11.020
Volume 245, March 2022, Pages 126-135
Female heart disease has for a long time been an underrecognized problem in the field of cardiology. With an ever-growing number of these patients getting pregnant, cardiac dysfunction during pregnancy is an increasingly large medical problem. Previous work has shown that maternal heart disease may have an adverse effect on pregnancy outcome in both mother and child. The placenta forms the connection and it is postulated that cardiac dysfunction negatively affects the placenta, and consequently, neonatal outcome. Given the paucity of data in this field, more research on the influence of cardiac (mal)function on placental (mal)function is needed. The present review describes placental function in women with various types of cardiac dysfunction, thereby aiming to provide more insight into possible underlying mechanisms of placental malfunction. Organ dysfunction in patients with heart failure is for an important part based on reduced perfusion and venous congestion. This has been shown in other organs such as kidneys, liver and brain. In pregnant women with cardiac dysfunction, placental dysfunction may follow similar patterns. Moreover, other factors, such as pre-existing hypertension and chronic hypoxia may lead to further impairment of placental function, through abnormal vascular remodeling of the uterine spiral arteries. The pathophysiology of placental dysfunction in pregnant women with cardiac dysfunction may thus be multifactorial. It is therefore important to monitor closely cardiac and placental function in such high-risk pregnancies. Gaining a better understanding of the underlying pathophysiological mechanisms may have important clinical implications in terms of pregnancy counseling, monitoring and outcome.
Dysglycemia and incident heart failure among blacks: The jackson heart study
Justin B.Echouffo-TcheuguiMD, PhDabStanford E.MwasongweMSbSolomon K.MusaniPhDcMichael E.HallMDcAdolfoCorreaMD, PhDcAdrian F.HernandezMD, MHSdSherita H.GoldenMD, MHSaRobert J.MentzMDdAlain G.BertoniMD, MPH.e
doi : 10.1016/j.ahj.2021.11.003
Volume 245, March 2022, Pages 1-9
Fibroblast growth factor-23 and subclinical markers of cardiac dysfunction: The coronary artery risk development in young adults (CARDIA) study
EhimareAkhabueMDaMandyWongMSbRupalMehtaMDbTamaraIsakovaMD, MMScbMylesWolfMD, MMScClydeYancyMD, MScbOrlando M.GutierrezMD, MMScdMercedesCarnethonPhDb
doi : 10.1016/j.ahj.2021.11.009
Volume 245, March 2022, Pages 10-18
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorbâ„¢-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose
C. MichaelGibsonMDaMichael J.MackMDbVictoria T.LeeMDcDavid J.SchneiderMDdFrank W.SellkeMDeE. MagnusOhmanMDfVinod H.ThouraniMDgGheorgheDorosPhDahHansKrogerMSccDonald E.CutlipMDaEfthymios N.DeliargyrisMDc
doi : 10.1016/j.ahj.2021.10.188
Volume 245, March 2022, Pages 19-28
Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation
J. AntonioGutierrezMD MHSabcRuff T.ChristianMD MPHdAaron W.AdayMD MSceLinGuMSaRyan D.SchulteisMDaLuShihaiPhDfMichaelaPetriniPA-C MHSfAlbert Y.SunMDabcRajesh V.SwaminathanMDabcDaniel R.KatzenbergerPharmD, BCPS, BCCPaSubhashBanerjeeMDghSunil V.RaoMDabc
doi : 10.1016/j.ahj.2021.11.008
Volume 245, March 2022, Pages 29-40
Delayed medical care due to transportation barriers among adults with atherosclerotic cardiovascular disease
IsaacAcquahMD, MPHaKobinaHaganMBChB, MPHaJavierValero-ElizondoMD, MPHabZulqarnainJavedPhD, MPH, MBBSaSara AyazButtMScaShiwaniMahajanMBBS, MHScdMohamad BadieTahaMDeAdnan A.HyderMD, MPH, PhDfEliasMossialosMD, MPH, PhDgMiguelCainzos-AchiricaMD, MPH, PhDabKhurramNasirMD, MPH, MScab
doi : 10.1016/j.ahj.2021.11.019
Volume 245, March 2022, Pages 60-69
In patients with atherosclerotic cardiovascular disease (ASCVD), barriers related to transportation may impair access to care, with potential implications for prognosis. Although few studies have explored transportation barriers among patients with ASCVD, the correlates of delayed care due to transportation barriers have not been examined in this population. We aimed to examine this in U.S. patients with ASCVD using nationally representative data.
Cardiac MRI predictors of good long-term outcomes in patients with repaired TOF
AmaraMajeedMBBSabTalGevaMDabLynn A.SleeperScDabJulia A.GrafBSaMinminLuMSaSonya V.Babu-NarayanMB BS, BSc, PhD, FRCPcRachel M.WaldMDdeBarbara J.M.MulderMD, PhDfgAnne MarieValenteMDabh
doi : 10.1016/j.ahj.2021.11.015
Volume 245, March 2022, Pages 70-77
Outcomes of prolonged dual anti-platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A nationwide registry-based study
Daniel MølagerChristensenMDaAnne-MarieSchjerningMD, PhDabCarolineSindet-PedersenMSc, PhDacMortenLambertsMD, PhDcJonas BjerringOlesenMD, PhDcCarlo AlbertoBarcellaMD, PhDcChristianTorp-PedersenMD, DMScdGunnarGislasonMD, PhDacJarl EmanuelStrangeMDa
doi : 10.1016/j.ahj.2021.11.018
Volume 245, March 2022, Pages 81-89
Randomized controlled trials have shown a reduced risk of ischemic events and an increased risk of bleeding in patients treated with prolonged dual anti-platelet therapy (DAPT) beyond 12 months following acute coronary syndrome (ACS). We aimed to investigate outcomes of prolonged DAPT vs aspirin monotherapy (ASA) in a real-world population.
Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines – Atrial Fibrillation (GWTG-AFIB) registry☆
Aditya J.UllalMDabDaJuanicia N.HolmesMScBarbara L.LytleMScRoland A.MatsouakaPhDcShubinShengPhDcNihar R.DesaiMD MPHeAnne B.CurtisMDfMargaret C.FangMD MPHgPamela J.McCabePhD RNhGregg C.FonarowMDiAndrea M.RussoMDjWilliam R.LewisMDkPaul A.HeidenreichMD MSabJonathan P.PicciniMD MHScMintu P.TurakhiaMD MASabdAlexander C.PerinoMDabd
doi : 10.1016/j.ahj.2021.12.002
Volume 245, March 2022, Pages 90-99
Tricuspid valve disease prevalence and the impact of tricuspid valve surgery on cardiovascular events and hospital resource use in medicare beneficiaries
SreekanthVemulapalliMDaMatthew S.D.KerrPhDbGregory J.RobertsbJulie B.PrillingerPhDbChristopher U.MeduriMD MPHcPatrickMcCarthyMDd
doi : 10.1016/j.ahj.2021.12.001
Volume 245, March 2022, Pages 100-109
Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction☆
Anthony P.CarnicelliMDabRobert M.ClareMSaPaulHofmannBSaKarenChiswellPhDaAdam D.DeVoreMD, MHSabSreekanthVemulapalliMDabG. MichaelFelkerMDabAnita M.KelseyMDabTracy A.DeWaldPharmDaPhilSaroccocRobert J.MentzMDab
doi : 10.1016/j.ahj.2021.12.003
Volume 245, March 2022, Pages 110-116
Harmonization of the definition of sudden cardiac death in longitudinal cohorts of the European Sudden Cardiac Arrest network – towards Prevention, Education, and New Effective Treatments (ESCAPE-NET) consortium
Peder EmilWarmingMDa#Frederik NybyeÃ…gesenMDa#Thomas HadbergLyngeMD, PhDaRezaJabbariMD, PhDaRobin L.A.SmitsMScbIrene G.M.van ValkengoedPhDbSabrina J.G.C.WeltenMSccAmber A.van der HeijdenPhDcPetra J.EldersMD, PhDcMarieke T.BlomPhDdXavierJouvenMD, PhDePeter J.SchwartzMDfChristine M.AlbertMD, MPHgJoline W.BeulensPhDhFemkeRuttersPhDhHanno L.TanMD, PhDdiJean-PhilippeEmpanaMD, PhDeJacobTfelt-HansenMD, DMScajESCAPE-NET Investigators
doi : 10.1016/j.ahj.2021.12.008
Volume 245, March 2022, Pages 117-125
Noninvasive echocardiographic cardiac power output predicts mortality in cardiac intensive care unit patients
BarryBursteinMDaVidhuAnandMBBSbBradleyTernusMDcMeirTabiMDbNandan S.AnavekarMBBChbBarry A.BorlaugMDbGregory W.BarsnessMDbGarvan C.KaneMDPhDbJae K.OhMDbJacob C.JentzerMDab
doi : 10.1016/j.ahj.2021.12.007
Volume 245, March 2022, Pages 149-159
Intestinal barrier dysfunction is associated with elevated right atrial pressure in patients with advanced decompensated heart failure
TakeshiKitaiMD, PhDabInaNemetPhDcTimothyEngelmanLPNaRommelMoralesMScThanatChaikijurajaiMDaKathrynMoralesMScStanley L.HazenMD, PhDacW.H. WilsonTangMDac
doi : 10.1016/j.ahj.2021.11.014
Volume 245, March 2022, Pages 78-80
We prospectively performed serial differential sugar absorption test in 29 consecutively consented patients with advanced decompensated heart failure admitted to the heart failure intensive care unit for hemodynamically-guided therapy. We observed that intestinal barrier function was significantly impaired in our study cohort, and increased intestinal permeability was associated with elevated right atrial pressure and poorer prognosis yet without any association with systemic levels of the gut microbial metabolite, trimethylamine N-oxide (TMAO) or intestinal fatty acid binding protein that were thought to be indicative of intestinal abnormalities.
